


USSN 10/762,907
37 C.F.R. § 1.111 Response
Page 2

Attorney Docket No. CT2739NP

Amendments to the Claims

1. (original) A compound of the formula



wherein the wavy bond (~~) represents the racemate, the (R)-enantiomer or the (S)-enantiomer;
R¹, R², R³, and R⁴ each are independently hydrogen or -P(O)OR⁵OR⁶;
R⁵ and R⁶ each are independently hydrogen or C₁₋₄ alkyl;
X is a covalent bond or -CR⁵R⁶O-;
or a nontoxic pharmaceutically acceptable salt or solvate thereof.

2. (original) The compound of claim 1 which is 3-(S)-(5-Chloro-2-methoxy-phenyl)-3-fluoro-6-trifluoromethyl-1-(3-(R), 4-(S), 5-(S)-trihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-1,3-dihydro-indol-2-one or a pharmaceutically acceptable salt or solvate thereof.
3. (original) The compound of claim 1 which is 3-(S)-(5-Chloro-2-methoxy-phenyl)-3-fluoro-6-trifluoromethyl-1-(3-(R), 4-(S), 5-(S)-trihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-2-(R)-yl)-1,3-dihydro-indol-2-one or a pharmaceutically acceptable salt or solvate thereof.
4. (original) The compound of claim 1 which is phosphoric acid mono-{2-(R)-[3-(S)-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxo-6-trifluoromethyl-2,3-dihydro-indol-1-yl]-4-(S), 5-(S)-dihydroxy-6-(R)-hydroxymethyl-tetrahydro-pyran-3-(R)-yl} ester or a pharmaceutically acceptable salt or solvate thereof.
5. (currently amended) A pharmaceutical composition for the treatment of disorders responsive to openers of the large conductance calcium-activated potassium channels, the disorders consisting of cerebral ischemia and stroke with the composition comprising a therapeutically effective amount of

USSN 10/762,907
37 C.F.R. § 1.111 Response
Page 3

Attorney Docket No. CT2739NP

a compound as defined in claim 1 in association with a pharmaceutically acceptable carrier or diluent.

6. (currently amended) A method for the treatment of disorders responsive to opening of the large conductance calcium-activated potassium channels in a mammal in need thereof, the disorders consisting of cerebral ischemia and stroke and the method ~~which~~ comprises administering to said mammal a therapeutically effective amount of a compound as defined in claim 1.

7. (cancelled)

7 | 8. (currently amended) The method of claim 7 6 wherein the disorder is stroke.

8 | 9. (currently amended) The method of claim 7 6 wherein the disorder is cerebral ischemia ~~traumatic brain injury~~.